ADRB3 and bacterial urinary tract infection: All patients were managed with invasive or noninvasive urotherapy, including antimuscarinics or beta-3 adrenoceptor agonists for DO, α-blockers with skeletal muscle relaxants for dysuria, and antibiotic treatment and prophylaxis for recurrent UTI.